Praxis Precision Medicines, Inc.
A biopharmaceutical company developing treatments for brain disorders like epilepsy and essential tremor, using two platforms—Cerebrum for small-molecule drugs and Solidus for antisense oligonucleotide therapies. Its lead candidates include ulixacaltamide for essential tremor and seizure-fighting drugs like relutrigine. Founded in 2015 as EpiPM Therapeutics, it took its name from the Greek "praxis," meaning "to do"—turning scientific theory into practical treatment.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| ORBIS INVESTMENT MANAGEMENT LTD | 13G/APassive | 5.5% | 1.53M | Aug 14, 2026 |
| Allan Gray Australia Pty Ltd | 13G/APassive | 0% | 3.1K | Aug 14, 2026 |
| Baker Bros. Advisors LP | 13GPassive | 6.3% | 1.75M | May 15, 2026 |
| Baker Bros. Advisors (GP) LLC | 13GPassive | 6.3% | 1.75M | May 15, 2026 |
| Julian C. Baker | 13GPassive | 6.3% | 1.75M | May 15, 2026 |
| Felix J. Baker | 13GPassive | 6.3% | 1.75M | May 15, 2026 |
| Point72 Biotech Private Investments, LLC | 13G/APassive | 0.2% | 65.9K | May 15, 2026 |
| Differentiated Ventures Investments, LLC | 13G/APassive | 0.2% | 65.9K | May 15, 2026 |
| 72 Investment Holdings, LLC | 13G/APassive | 0.2% | 65.9K | May 15, 2026 |
| Steven A. Cohen | 13G/APassive | 0.2% | 65.9K | May 15, 2026 |